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Deep sequencing of human papillomavirus
positive loco-regionally advanced
oropharyngeal squamous cell carcinomas
reveals novel mutational signature
Christian Grønhøj1† , David H. Jensen1†, Tina Agander2, Katalin Kiss2, Estrid Høgdall3, Lena Specht4,
Frederik Otzen Bagger5, Finn Cilius Nielsen5 and Christian von Buchwald1*
Abstract
Background: The genetic profile for human papilloma virus positive (HPV+) oropharyngeal squamous cell carcinomas
(OPSCC) remains largely unknown. The purpose of this study was to sequence tissue material from a large cohort of
locoregionally-advanced HPV+ OPSCCs.
Methods: We performed targeted deep sequencing of 395 cancer-associated genes in 114 matched tumor/normal
loco-regionally advanced HPV+ OPSCCs. Mutations and copy number aberrations were determined.
Results: We identified a total of 3459 mutations with an average of 10 mutations per megabase and a median of 28
variants per sample. The most frequently mutated genes were KALRN (28%), SPTBN1 (32%), KMT2A (31%), ZNRF3 (9%),
BNC2 (12%), NOTCH2 (25%), FGFR2 (12%), SMAD2 (6%), and AR (13%). Our findings were dominated by COSMIC signature
5 and 12, represented in other head and neck cancers and in hepatocellular carcinomas, respectively.
Conclusions: We have identified multiple genetic aberrations in HPV+ OPSCCs, and the COSMIC signature 12 as most
prevalent. The mutations harbour both therapeutic and prognostic potential.
Keywords: Gene sequencing, Deep sequencing, HPV, Human papilloma virus, Oropharyngeal cancer
Background
Head and neck squamous cell carcinoma (HNSCC) is
among the most prevalent cancers worldwide partly due
to the growing number of oropharyngeal squamous cell
carcinomas (OPSCCs) associated with human papillo-
mavirus infection (HPV+) [1, 2]. Compared with the
HPV-negative OPSCCs, this subset of cancer is associ-
ated with favourable outcome likely explained by a dif-
ference in immunological [3], clinical [4, 5], and
histopathological features [6]. Consequently, the interest
in the mutational profile of HPV-associated HNSCCs is
growing.
High-throughput DNA sequencing has led to identifi-
cation of alterations in genes and pathways involved in
the tumorigenic processes. With the exception of two
smaller studies addressing structural DNA changes and
mutations in HPV+ OPSCCs [7–9], large-scale studies
have primarily mapped the diverse genetic landscape of
HPV negative HNSCCs [10, 11]. Unlike a number of
adenocarcinomas, no targetable genetic aberrations for
OPSCCs are approved for treatment or as prognostic
biomarkers. OPSCC patients are generally treated
according to stage; typically for advanced disease with
radiation, chemotherapy, or both, and for low stage
disease surgery. The anti-EGFR-antibody (e.g. cetuxi-
mab) is the only approved targeted therapy but is has
shown low to moderate effect in single-drug trials, and
no convincing results as predictive biomarker [12–14].
Our knowledge about the mutational profile for HPV+
OPSCCs is incomplete, but carries the prospect of
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identification of targets for drug intervention as well as
prognostic biomarkers for patient stratification in trial
design. The purpose of this study is to present a com-
prehensive assessment of genetic aberrations in
loco-regionally advanced HPV+ OPSCCs.
Methods
We included 114 matched tumor- and normal tissues
from patients diagnosed with a HPV+ OPSCC in eastern
Denmark [1, 15, 16]. The patients were identified
through the Danish Head and Neck Cancer group
(DAHANCA) database and validated through the na-
tional Danish Pathology Data Registry (DPDR). An ex-
pert head and neck pathologist validated the diagnosis of
OPSCC from a hematoxylin and eosin (H&E-) stained
section of each tumour. The p16-staining was consid-
ered positive if a strong and diffuse nuclear and cyto-
plasmic reaction was present in more than 75% of the
tumour cells [17]. Formalin-fixed paraffin embedded
(FFPE) tumour specimens was handled according to
standard operating procedures for the p16 immunohis-
tochemistry. The protocol for p16 immunohistochemis-
try and HPV DNA PCR is previously described in detail
[1, 16]. Smoking was quantified in number of pack-years
(one pack year equals 20 cigarettes per day for one year),
and data was collected from medical files. From an
H&E-stained section, tumor and normal tissue was con-
toured by a head and neck pathologist. Tumor and nor-
mal tissue was subsequently punched biopsied from the
FFPE-block to avoid contamination.
Sequencing data generation and analysis
A custom panel of 395 cancer-associated genes
(Additional file 1: Table S1) were targeted and sequenced
in tumour-normal pairs. Genes were identified via
cBioportal.org and selected based on results from The
Cancer Genome Atlas [18], Agrawal et al. [19], and
Rubio-Perez et al. [20]. Median coverage of the targeted
bases was 150X in the tumours and 200X in the
matched normal tissue.
DNA extraction
Deamination of cytosine bases to uracil is a known
source of DNA damage occurring in FFPE blocks that
may lead to cytosine-thymine conversion (artefacts) in
PCR and/or sequencing reactions [21], that can be ame-
liorated with the use of an Uracil-N-Glycosylase [22].
Therefore, we used the commercial GeneRead DNA
FFPE Kit (Qiagen, Hilden, Germany), which is based on
specific removal of deaminated cytosine residues from
FFPE DNA using the Uracil-N-Glycosylase enzyme. The
kit was used with the manufacturer’s instructions, except
for the use of double amount of proteinase K and
deparaffination solution, and samples were left overnight
for proteinase K digestion at 56 °C.
Library preparation and sequencing
Genome libraries were prepared according to the Ovation
Custom Target Enrichment System protocol (NuGen).
Landing-probes were designed by NuGEN to target the
chosen genes. Target enrichment and library preparation
was done according to the manufacturer’s protocol
(NuGEN Technologies, San Carlos, CA). Briefly, genomic
DNA was fragmented, end-repaired and ligated with
forward barcoded adaptors, followed by a bead purifica-
tion step. The barcoded adaptor contained both an 8-nt
sample-specific barcode and a 6-nt UMI. The latter was
used to identify and remove duplicate reads. The reverse
adaptor was annealed to the target regions and extended.
The library amplification step comprised 25 PCR cycles
followed by bead purification and sequencing. Sequencing
was carried out on a NextSeq 500 (Illumina Inc., San
Diego, CA) with single-end sequencing (150-bp) using the
high-output kit v2.
Bioinformatics analysis
Raw sequencing data (.bcl files) were demultiplexed into
individual FastQ read files with Illumina’s bcl2fastq
v2.16.0.10 (Illumina Inc., San Diego, CA) based on their
unique index, with the R1 read containing the forward
read and R2 containing the UMI. Each sequencing library
was checked for quality with fastQC (version 0.11.5). A
combination of cutadapt (version 1.11), BBDuk (version
35.82) and ERNE-filtering (version 2.1.1) was employed to
remove adapter and linker sequences, remove trailing
probe sequence on R1, and clip low-quality bases ends.
Read alignment was carried out with the BWA algorithm
(BWA version 0.7.10) with UCSC hg19 (GRCh37) as the
reference. Deduplication was performed with an in-house
script developed at IGA Technology (http://igatechnolo-
gy.com), which makes use of the UMI to accurately
remove PCR duplicates. The deduplicated reads were sub-
sequently prepared for variant calling after realignment to
correct for misalignments around indels and recalibrating
base qualities based on known polymorphisms present in
the human dbSNP (dbSNP137) with the GATK tool
(v3.6–0-g89b7209). Variants were called with Mutect2
based on tumour-normal pairs with standard settings.
Only mutations that passed Mutect2 filters were used in
the downstream analysis. We performed a filtering step
before annotation, where SNPs present in the European
1000 Genomes cohort [23] with an allele frequency above
1% were removed, as they are more likely to represent
common population polymorphisms than somatic muta-
tions. We also filtered SNPs that did not full-fill the
following criteria: Number of mutant allele reads in
tumour sample ≥ 5, total number of allele reads ≥20,
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quality score (QSS) > 20 and variant allele fraction > 0.1, in
order better to exclude C > T variants associated with
FFPE artefacts [24]. To account for false positive variants
from Mutect2 samples with a SQSS > 20 was filtered,
where SQSS is QSS/allelic depth in the tumour [25]. For
annotation, we used Oncotator v. 1.8.1.0 [26]. For
visualization of mutations we used maftools [27]. Somatic
genes that were significantly mutated were identified using
OncodriveFML 1.1 using a threshold of q < 0.1 with
CADD v.1.3, a signature by cancer type and coding re-
gions [28]. Mutational signatures were predicted in each
sample using the COSMIC framework [29]. Substitution
mutations across the whole genome were analysed in con-
text of the flanking nucleotides (96 possible trinucleotide
combinations). Identified signatures were compared with
30 other validated signatures, and the frequency of each
signature per megabase was determined. The numbers of
enriched mutational signatures were established by a
best-fit rank based on decreasing cophenetic correlation
coefficients. Apolipoprotein B mRNA editing enzyme, cata-
lytic polypeptide-like (APOBEC) enrichment scores were
estimated as described by Burns et al. [30]. Briefly, enrich-
ment of C > T mutations occurring within a tri-nucleotide
DNA sequence (tCw) motif over all of the C > T mutations
in a given sample was compared to background cytosine
ratio and tCw’s occurring within 20 bp of mutated bases.
Samples were classified as APOBEC-enriched based on an
APOBEC enrichment score > 2 and/or false discovery rate
(FDR) < 0.05. DNA copy number variations (CNV) were
predicted by analysing the panel-sequencing data using
CNVPanelizer, which compares tumour samples with a
pool of normal tissue samples. The algorithm combines
bootstrapping the reference set with the subsampling of
amplicons associated with each of the target genes. This
serves as a non-parametric estimation of the distribution of
the gene-wise mean ratio between healthy reference sam-
ples and each tumour sample. All normal samples were
used as a reference for calculating the sample-wise CNVs.
Only genes that passed the noise and significance filter are
reported as amplifications or deletions. To compare the
difference in mutations between patients with high and low
exposure to tobacco, we performed a fisher test on all genes
between the two conditions to detect differentially
mutated genes.
Results
We sequenced 114 locoregionally-advanced HPV-positive
oropharyngeal squamous cell carcinomas. The targeted
sequencing from 395 genes identified a total of 3459
mutations with an average of 10 mutations per megabase
(excluding silent variants). The majority of mutations were
missense mutations (86%), and less common mutations
were frame-shift-deletions (5%), splice-site mutations (5%)
and non-sense mutations (4%) (Fig. 1). The majority of
identified mutations were SNPs, but deletions and inser-
tions (indels) were also identified (Fig. 1). Of the 114 tu-
mours 96% (n = 110) were HPV+/p16+ and the remaining
HPV+/p16-.
Mutation signatures
The predominant type of SNV was found to be C > T
and T > C (Figs. 1 and 2). The DNA substitution muta-
tions were most commonly transitions (Fig. 2). The
mutational pattern of each sample was compared against
all 30 validated mutational signatures from COSMIC
[29]. This was assessed by the COSMIC algorithm that
takes the sequence context of each mutation into
account (Fig. 3). The tumours were dominated by COS-
MIC signature 5 or 12 (Figs. 2 and 3). Signature 5 has
previously been observed to be enriched in HNSCC.
The signature is depicted in most cancers and exhibits
transcriptional strand bias for T > C substitutions at an
ApTpN context [31]. Signature 12 is known to be
present in a subset of liver cancers, and exhibits a strong
transcriptional strand-bias for T > C substitutions [31]. It
was also investigated whether an APOBEC signature was
significantly enriched in our samples. The APOBEC
signature was enriched in a quarter of the samples (23%)
[30] (Additional file 2: Figure S1).
Somatic driver mutations
The OncodriveFML (q < 0.05) tool was employed to iden-
tify genes enriched in mutations. This algorithm identified
167 significantly mutated genes (Fig. 4). Of these APOB
(35%), BIRC6 (32%), SPTBN1 (32%), FAT2 (32%), KMT2A
(31%), FAT1 (30%), BPTF (30%), TRIO (30%), HERC2
(28%), and KALRN (28%) were among the most frequently
mutated genes. The most prevalent genomic alterations
were located in KALRN (28%), SPTBN1 (32%), KMT2A
(31%), ZNRF3 (9%), BNC2 (12%), NOTCH2 (25%), FGFR2
(12%), SMAD2 (6%), and AR (13%).
Copy-number alterations
We determined CNAs from our sequencing panel by
employing CNVPanelizer, an algorithm specifically
designed to estimate copy number frequencies using
targeted massive parallel sequencing data. The most
frequent gene copy gain was detected for ATF68 (n = 83;
72% of samples) and IL3RA (n = 81; 71% of samples).
We found a high level of inter-patient CNA heterogen-
eity, but also a high intra-patient CN heterogeneity.
Mutant-allele tumour heterogeneity scores
In the cohort, we identified the mutant-allele tumour
heterogeneity (MATH) score. The median score was
20.8 (range 8–36) (Additional file 3: Figure S2).
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Effect of smoking
Information on smoking was available for 70 patients with
a median number of pack years of 15 (95% CL: 1.5–20 pack
years). Thirty patients had never smoked or had less than
10 pack years. The genetic aberrations differed significantly
between smokers and non-smokers. For smokers the genes
FGFR2, EPHA2 were significantly more likely to be mu-
tated. For non-smokers the genes IREB, BAZ2 and BRCA1
were significantly more often mutated. The mutational sig-
nature for those with low tobacco use was signature 5 and
signature 12 in that order. The mutational signature for
those with high tobacco use was in contrast 12 and 5. We
did not observe any significant difference in MATH score
between those with high and low tobacco use. There was
also no significant increase in mean number of mutations
per sample between these two groups.
Discussion
Here we present the targeted mutation spectrum of a large
cohort of HPV-positive OPSCCs. We corroborate previously
reported aberrations (e.g. FGFR, PIK3, FAT1, NOTCH2), but
also more rare alterations in HPV-positive OPSCCs (e.g.
KALRN, KMT2A, and SPTBN1) [11, 20, 32]. Our finding of
3459 mutations with an average of 10 mutations per mega-
base is higher than that in the TCGA HNSCC cohort [33],
which may be explained by the fact that the TCGA cohort is
predominately HPV-negative tumours.
Among human cancers, TP53 is the most frequently
mutated gene, and TCGA data has shown that p53 ‘gai-
n-of-functions’ mutants bind to, and upregulate, several
chromatin regulatory genes including the methyltrans-
ferases MLL1 – also known as KMT2A – which is highly
prevalent in our cohort (31%) [34]. A chromatin mech-
anism causal for the progression of tumours with
gain-of-function p53 prospects possibilities in the design
of combinatorial chromatin-based therapies [34]. Aber-
rations in SPTBN1, that encodes a scaffolding cellular
protein involved in the formation of the cytoskeleton, is
a useful prognostic biomarker in HPV-negative HNSCCs
since patients with tumours expressing SPTBN1 have
Fig. 1 Top left: Number of mutations by type. Top middle: number of mutations by mutation type. Top right: Number of SNVs by type of variation.
Bottom left: Number of variants per sample. Bottom middle: Type of variation. Bottom right: Top 10 mutated genes and type of mutations seen.
Abbreviations: SNP: Single nucleotide polymorphism, INS, insertion, DEL, deletion. Green colour (missense mutation). Blue colour (Frame shift deletion).
Orange (Splice site mutation). Red colour (nonsense mutation). Purple (Frame shift insertion)
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four times higher mortality, compared with patients not
harbouring this mutation [35]. Although Zhu et al. ex-
amines gain-of-function, our data indicates that this
gene is also prevalent in HPV+ OPSCCs and could be
prognostic in these tumours as well. The known cancer
gene ZNRF3 belonging to the E3 ubiquitin ligase family
was also frequent in our cohort (9% of samples). Previ-
ously, it has been reported that ZNRF3 has the ability to
inhibit the metastasis and tumorigenesis by suppressing
the Wnt/β-catenin signalling pathway in nasopharyngeal
carcinomas (NPC), hence believed to be a potential
molecular target for treatment of NPC. Based on our
results, it should also be considered in HPV+ OPSCCs
[36]. Due to availability of existing therapeutics and high
prevalence of mutations in HPV+ OPSCC, patients with
PIK3CA and CDK4/CDK6 mutations should be recom-
mend for future phase 0 and I trials. Notably, in our
cohort, we merely identified an occurrence of 7 and 1%
related to PIK3CA pathways and CCND1 aberrations.
Further, the FGFR2/3 mutations are of particular interest
because they were present in 20% of the tumours, in
particular the S249C mutation, which is an oncogenic
driven in bladder cancer [20]. Upon binding of ligand,
FGFRs activate a cascade of downstream signalling path-
ways, such as the mitogen activated protein kinase
(MAPK), phosphoinositide-3-kinase (PI3K)/Akt path-
ways signal transducer and activator of transcription
(STAT). The mutated FGFR isoforms result in oncogenic
FGFR signalling, promoting tumorigenesis, and the de-
fect FGFR signalling pathway is a major contributing
factor in the pathogenesis and progression of HNSCC
[37, 38]. Inhibition of FGFRs is a promising therapeutic
strategy, and phase I and II trials are progressing [39,
40] The tumor suppressor TRAF3 has previously been
brought forward as a potential target for therapy devel-
opment as it was inactivated in 20% of the HPV-positive
tumors in the TCGA cohort. [10] Interestingly, we only
identified 5% tumors with this alteration in our cohort.
A previous study [41] has focused on mutations in
HPV-positive and HPV-negative patients in a mixed
population of larynx, oral cavity, oropharynx and hypo-
pharynx cancer patients. In this study, a high prevalence
of PIK3CA alterations (mutations and amplifications) was
evident, which is not the case in the present study. We
speculate that this could be related to 1) a high prevalence
of smoking in the present study, 2) ethnical dissimilarities,
and 3) the definition of being HPV-positive (RNA-sequen-
cing versus HPV-DNA PCR). These factors could influ-
ence the carcinogenic process (smoking vs. no smoking)
as well as perhaps not examining the exact same
phenotype (being HPV-DNA PCR positive vs. RNA-seq
positive for E6/E7), and perhaps tissue specific muta-
tional processes (oropharynx vs. other head and neck
cancer subsites).
Other studies evaluating HPV+ OPSCC consistently
report mutations in PIK3CA as well as PTEN, TRAF3,
NOTCH1. Although, we did identify these aberrations,
they were not among the twenty most prevalent muta-
tions in our cohort. This could be explained by the de-
duction that these aberrations are not as prevalent in
Fig. 2 Top panels: Percentage of mutations belonging to the specified
type of variant and percentage of transitions (Ti) and transversions (Tv).
Lower panels: Contribution the signatures for each patient
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Denmark as other countries, or the fact that our speci-
mens or probes were not adequate set for identifying
these mutations.
Interestingly, IL3RA, HLA-A and HLA-B have copy
number gains in HPV positive oropharyngeal cancers [3,
42]. Absence of HLA class I (HLA-A and –B) in HPV+
OPSCC has indicated improved outcome which could
be used clinically to select patients for trials with
de-escalating therapy. The understanding between the
genetic background of OPSCC patients and HLA-traits
remains incomplete as several HLA-traits have been
associated to altered outcome [43, 44].
The landscape of HPV+ and HPV- OPSCCs point to
different signatures and structural alterations [11]. To
stratify HPV+ from HPV- patients, the most obvious aber-
rations from our cohort would include KALRN, FGFR2
and NOTCH2 which are rare in HPV- HNSCC. The
NFE2L2 pathway as well as the promising PIK3CA muta-
tion and CCND1 amplication should also be prioritized.
From the TCGA cohort, the majority of driver muta-
tions were found to be clonal (e.g. “early” mutations op-
posed to subclonal viewed as “late” mutations) where
CDKN2A and TP53 were nearly completely clonal [45].
McGranahan et al. identified three “early” signatures in
HNSCC: 1) C > T transitions at CpG sites associated with
spontaneous deamination of methylated cytosines; 2) an
APOBEC-signature (also seen in “late” mutations); and 3)
a smoking-associated signature. In our material, we also
identify the APOBEC signature in 23% of the tumors, like-
wise reported in other HPV+ HNSCCs series [46].
We observed a significant increase in the COSMIC
signature 12 associated with certain virus-driven liver
cancers. Interestingly, a trial related to these aberrations
is progressing. Ribavirin, that target the eIF4E translation
initiation factor, is used to treat hepatitis C, and is under
investigation for recurrent or metastatic OPSCC (Clini-
calTrials.gov, NCT02308241). Ribavirin is also being
evaluated along with induction chemotherapy including
afatinib (a tyrosine kinase inhibitor) and weekly carbo-
platin/paclitaxel for stage IV HPV-associated OPSCC
(ClinicalTrials.gov, NCT01721525). Additionally for HPV
+ OPSCC patients with recurrent or metastatic disease,
rigosertib (a PI3K (phosphatidylinositol-3 kinase) and PLK
(Polo-like kinase) signalling pathway inhibitor) is being
investigated in a phase II trial (ClinicalTrials.gov,
NCT01807546), and in a phase I trial used as initial
treatment before platinum based RT-C (ClinicalTrials.gov,
NCT02107235). For high risk HPV+ OPSCC patients, the
PI3K inhibitor, BYL719, is being tested with induction
paclitaxel and cisplatin followed by T-site surgery,
neck-disssection, and with post-operative risk adapted
IMRT (ClinicalTrials.gov identifier, NCT02298595).
Although this study is strengthened by a setup, that in-
cludes a deep coverage, a high number of genes, and
HPV and p16 status of all patients to ensure HPV-active
infections, some limitations should be noted. First, there
may be a selection bias both in patients but also because
we employed a gene panel. Moreover, the particular
selection of genes might influence the findings, since we
have included quite large genes (e.g. APOB) where an
alteration is more likely opposed to smaller genes. The
sub analysis including tobacco merely includes 70
patients due to missing data and a higher number of pa-
tients might lead to other findings. Finally, as described
Fig. 3 Panel (Top Panel) Correlation plots for signatures for all patients. Panel (Middle Panel) Correlation plots for signatures for patients with high
tobacco smoking consumption. Panel (Lower Panel) Correlation plots for signatures for patients with low tobacco smoking consumption
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in “Methods” section, we strained to reduce artefacts
from the use of FFPE tissue (e.g. in the data analysis
and tissue preparation) although it should be included
as a probable source of bias. Tumor mutational bur-
den (TMB) in the present study was defined as the
median number of mutations per megabase examined
in the targeted sequencing. As the present study
concerns genes previously known to be implicated in
carcinogenesis, the TMB would be expected to be
higher than studies concerning TMB from e.g.
exome-sequencing studies, as there would be fewer
mutations per examined base.
When breaking down cosmic signatures from the
non-smokers and smokers, we did not observe any dif-
ference in enriched cosmic mutational signatures. When
looking at mutational signatures in the APOBEC
enriched and non-enriched groups, the signature 5 was
not enriched in the APOBEC-enriched group, but rather
the signature 2. Signature 2 has been attributed to activ-
ity of the AID/APOBEC family of cytidine deaminases,
and has been related to viral infections.
Both tobacco smoking and defects in DNA repair are
known to induce a large number of genetic aberrations,
and may be distinct ways to accumulate genetic
Fig. 4 Mutations in significantly mutated genes from OncodriveFML sorted by q-value. Top panel: Total coding mutations per sample. Right:
-10log(q-value). Lower panel: Top Panel Type of mutation with frequency in cohort given at the left. Lower Panel The most frequent deletions
and copy number alterations in the cohort from CNVpanelizer. At the top of this panel is a histogram depicting the frequency of the alteration in
the entire cohort
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aberrations required for the emergence of cancer. We
found a significant difference between smokers and
non-smokers underlining the importance of including
tobacco-smoking consumption in prediction models and
risk-stratifications. It is likely that the HPV-positive
smokers acquire tobacco-related mutations but maintain
virus related signatures. Even when stratified on
smoking-consumption (none-smokers vs. heavy smokers),
a large inter-tumor heterogeneity exists. Thus, if the fu-
ture aim is to offer a personalized treatment approach it
may require a very large battery of anticancer targeted
drugs. Although fast-moving technologies have prompted
the capability of identifying genetic aberrations promptly
and precisely, it remains largely unknown which thera-
py(−ies) to offer based on the combinations of driver muta-
tions. In order to fuel the development of targeted clinical
trials and diagnostic testing, confirmatory studies address-
ing genetic aberrations in HPV+ OPSCC are needed.
Conclusion
In conclusion, HPV+ OPSCCs harbour multiple genetic
aberrations with both therapeutic and prognostic poten-
tial. The discovery of signatures and shared mutations
from across organs (i.e. liver, lung and esophagus SCCs)
might speed the progress of phase II and III trials, and
should be incorporated in drug testing, especially for the
heavy smokers.
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